Incyte shares slide 3.86% and underperform rivals

10 articles · Updated · MarketWatch · Apr 30

The stock closed at $95.27 as the S&P 500 rose 1.02% and the Dow gained 1.62% in a broadly positive US market session.
The decline ended a three-day winning streak, leaving Incyte 15.16% below its 52-week high of $112.29 reached on 7 January.
Incyte lagged peers including Alnylam and Bio-Techne, while trading volume rose to 2.4 million shares, above its 50-day average of 1.6 million.

Incyte beat earnings expectations, so why did its stock price suddenly plummet by nearly 4%?

With its blockbuster drug's patent expiring soon, can Incyte's new pipeline secure its future growth?